SI2305250T1 - Benzimidazolni derivati in njih uporabo kot inhibitorji protein-kinaz - Google Patents
Benzimidazolni derivati in njih uporabo kot inhibitorji protein-kinazInfo
- Publication number
- SI2305250T1 SI2305250T1 SI200432146T SI200432146T SI2305250T1 SI 2305250 T1 SI2305250 T1 SI 2305250T1 SI 200432146 T SI200432146 T SI 200432146T SI 200432146 T SI200432146 T SI 200432146T SI 2305250 T1 SI2305250 T1 SI 2305250T1
- Authority
- SI
- Slovenia
- Prior art keywords
- protein kinases
- benzimidazole derivatives
- kinases inhibitors
- inhibitors
- benzimidazole
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48468503P | 2003-07-03 | 2003-07-03 | |
GBGB0315657.7A GB0315657D0 (en) | 2003-07-03 | 2003-07-03 | Pharmaceutical compounds |
US51437403P | 2003-10-24 | 2003-10-24 | |
GB0324919A GB0324919D0 (en) | 2003-10-24 | 2003-10-24 | Pharmaceutical compounds |
EP10195498.0A EP2305250B1 (en) | 2003-07-03 | 2004-07-05 | Benzimidazole derivatives and their use as protein kinases inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2305250T1 true SI2305250T1 (sl) | 2014-06-30 |
Family
ID=46045485
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200432125T SI1648426T1 (sl) | 2003-07-03 | 2004-07-05 | Derivati benzimidazola in njih uporaba kot inhibitorji proteinskih kinaz |
SI200432146T SI2305250T1 (sl) | 2003-07-03 | 2004-07-05 | Benzimidazolni derivati in njih uporabo kot inhibitorji protein-kinaz |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200432125T SI1648426T1 (sl) | 2003-07-03 | 2004-07-05 | Derivati benzimidazola in njih uporaba kot inhibitorji proteinskih kinaz |
Country Status (15)
Country | Link |
---|---|
US (3) | US7977477B2 (sl) |
EP (2) | EP1648426B1 (sl) |
JP (1) | JP4833059B2 (sl) |
CN (1) | CN1845734B (sl) |
AU (1) | AU2004253338B2 (sl) |
CA (1) | CA2531050C (sl) |
DK (2) | DK1648426T3 (sl) |
ES (2) | ES2443995T3 (sl) |
MX (1) | MXPA05014223A (sl) |
NZ (1) | NZ543959A (sl) |
PL (2) | PL2305250T3 (sl) |
PT (2) | PT2305250E (sl) |
SI (2) | SI1648426T1 (sl) |
TW (1) | TWI372050B (sl) |
WO (1) | WO2005002552A2 (sl) |
Families Citing this family (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI372050B (en) * | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
WO2005012256A1 (en) | 2003-07-22 | 2005-02-10 | Astex Therapeutics Limited | 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
WO2005075435A1 (en) * | 2004-01-30 | 2005-08-18 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US20080004270A1 (en) * | 2004-07-05 | 2008-01-03 | Astex Therapeutics Limited | 3,4-Disubstituted Pyrazoles as Cyclin Dependent Kinases (Cdk) or Aurora Kinase or Glycogen Synthase 3 (Gsk-3) Inhibitors |
US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
WO2006050506A1 (en) * | 2004-11-03 | 2006-05-11 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
JP2008526721A (ja) * | 2004-12-30 | 2008-07-24 | アステックス、セラピューティックス、リミテッド | Cdk、gsk及びオーロラキナーゼの活性を調節するチアゾールおよびイソチアゾール誘導体 |
WO2006070198A1 (en) * | 2004-12-30 | 2006-07-06 | Astex Therapeutics Limited | Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
NZ555982A (en) * | 2004-12-30 | 2011-01-28 | Astex Therapeutics Ltd | Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases |
WO2006077428A1 (en) | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Pharmaceutical compounds |
US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
KR101345002B1 (ko) * | 2005-01-21 | 2013-12-31 | 아스텍스 테라퓨틱스 리미티드 | 제약 화합물 |
AR052559A1 (es) * | 2005-01-21 | 2007-03-21 | Astex Therapeutics Ltd | Derivados de pirazol para inhibir cdk's y gsk's |
WO2006085685A1 (ja) * | 2005-02-09 | 2006-08-17 | Takeda Pharmaceutical Company Limited | ピラゾール化合物 |
WO2006108489A1 (en) | 2005-04-14 | 2006-10-19 | F. Hoffmann-La Roche Ag | Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents |
EP1749523A1 (en) | 2005-07-29 | 2007-02-07 | Neuropharma, S.A. | GSK-3 inhibitors |
US8093401B2 (en) | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
ES2431050T3 (es) * | 2005-08-04 | 2013-11-22 | Sirtris Pharmaceuticals, Inc. | Benzotiazoles y tiazolopiridinas como moduladores de la sirtuína |
US8088928B2 (en) | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
US7855289B2 (en) | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
EP2377530A3 (en) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
WO2007053596A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
BRPI0619517A2 (pt) * | 2005-12-08 | 2011-10-04 | Novartis Ag | ácidos pirazolo[1,5-a]piridina-3-carboxìlicos como inibidores de ephb e vegfr2 cinase |
JP2009519279A (ja) * | 2005-12-15 | 2009-05-14 | エフ.ホフマン−ラ ロシュ アーゲー | 三員環ラクタム誘導体、それらの製造方法、及び医薬剤としての使用 |
US7572809B2 (en) | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
EP1968579A1 (en) * | 2005-12-30 | 2008-09-17 | Astex Therapeutics Limited | Pharmaceutical compounds |
KR20070077468A (ko) * | 2006-01-23 | 2007-07-26 | 크리스탈지노믹스(주) | 단백질 키나아제 활성을 저해하는 이미다조피리딘 유도체,이의 제조방법 및 이를 함유하는 약학 조성물 |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
JP2009536669A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス,インコーポレイティド | アンジオテンシン調節による神経新生 |
JP5523829B2 (ja) * | 2006-06-29 | 2014-06-18 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
US20110159111A1 (en) * | 2006-06-29 | 2011-06-30 | Astex Therapeutics Limited | Pharmaceutical combinations |
FR2903406B1 (fr) * | 2006-07-04 | 2012-08-10 | Aventis Pharma Sa | Derives de pyrazolylbenzimidazole,compositions les contenant et utilisation |
EP2086970B1 (en) * | 2006-08-24 | 2014-02-26 | Novartis AG | 2-(pyrazin-2-yl)-thiazole and 2-(1h pyrazol-3-yl)-thiazole derivatives as well as related compounds as stearoyl-coa desaturase (scd) inhibitors for the treatment of metabolic, cardiovascular and other disorders |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
BRPI0718509A2 (pt) | 2006-09-22 | 2015-09-29 | Novartis Ag | compostos orgânicos heterocíclicos |
US20100022404A1 (en) * | 2006-10-05 | 2010-01-28 | Shinichi Hasako | Gene/protein marker for prediction or diagnosis of pharmacological efficacy of aurora a inhibitor |
MX2009003793A (es) | 2006-10-09 | 2009-12-14 | Takeda Pharmaceutical | Inhibidores de cinasa. |
US8916552B2 (en) | 2006-10-12 | 2014-12-23 | Astex Therapeutics Limited | Pharmaceutical combinations |
EP2073807A1 (en) | 2006-10-12 | 2009-07-01 | Astex Therapeutics Limited | Pharmaceutical combinations |
EP2125683B1 (en) | 2006-12-19 | 2013-10-23 | The Board of Trustees of the University of Illinois | 3-benzofuranyl-4-indolyl-maleimides as potent gsk-3 inhibitors for neurodegenerative disorders |
CN101595105B (zh) | 2006-12-20 | 2013-01-23 | 诺瓦提斯公司 | 作为scd抑制剂的2-取代的5元杂环化合物 |
DE102006060598A1 (de) * | 2006-12-21 | 2008-06-26 | Merck Patent Gmbh | Tetrahydrobenzoisoxazole |
CL2008001822A1 (es) | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras. |
WO2009058730A1 (en) * | 2007-10-29 | 2009-05-07 | Schering Corporation | Diamido thiazole derivatives as protein kinase inhibitors |
MX2010004875A (es) * | 2007-10-29 | 2010-05-19 | Schering Corp | Derivados de tiazol y metodos para utilizarlos. |
WO2009065131A1 (en) | 2007-11-16 | 2009-05-22 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
US8129390B2 (en) | 2007-12-12 | 2012-03-06 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds and methods for using the same |
EA021464B1 (ru) * | 2008-01-22 | 2015-06-30 | Вернэлис (Р&Д) Лтд. | Производные индол-пиридона, обладающие ингибиторной активностью в отношении киназы 1, содержащая их фармацевтическая композиция и их применение |
ES2552549T3 (es) | 2008-04-23 | 2015-11-30 | Rigel Pharmaceuticals, Inc. | Compuestos de carboxamida para el tratamiento de trastornos metabólicos |
US9265734B2 (en) | 2008-09-03 | 2016-02-23 | Biomarin Pharmaceutical Inc. | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors |
PE20131197A1 (es) | 2008-10-31 | 2013-11-06 | Genentech Inc | Compuestos de pirazolopirimidina como inhibidores de jak y composiciones farmaceuticas que los contienen |
AU2009318719A1 (en) * | 2008-11-20 | 2011-06-30 | Oncotherapy Science, Inc. | Glycogen synthase kinase-3 beta inhibitors containing 7-hydroxy-benzoimidazole-4-yl-methanone derivatives |
US8318928B2 (en) * | 2008-12-15 | 2012-11-27 | Glenmark Pharmaceuticals, S.A. | Fused imidazole carboxamides as TRPV3 modulators |
UA104447C2 (uk) | 2008-12-19 | 2014-02-10 | Сіртріз Фармасьютікалз, Інк. | Тіазолопіридинові сполуки, що модулюють сиртуїн |
CA2747326C (en) | 2008-12-22 | 2017-05-16 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-cd20 antibodies |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
UA103918C2 (en) | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
EP2445885A4 (en) * | 2009-06-25 | 2012-11-28 | Medolution Ltd | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CHINESE INHIBITORS AND METHOD FOR THEIR USE |
UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
RU2012120784A (ru) * | 2009-11-12 | 2013-12-20 | Селвита С.А. | Соединение, способ его получения, фармацевтическая композиция, применение соединения, способ модулирования или регулирования сериновых/треониновых киназ и средство, модулирующее сериновые/треониновые киназы |
CN101857589B (zh) * | 2010-06-08 | 2013-12-18 | 东南大学 | 吡唑-苯并咪唑类衍生物及其应用 |
CA2802641C (en) * | 2010-07-13 | 2019-03-12 | Nidhi Arora | Pyrazolo [1, 5a] pyrimidine and thieno [3, 2b] pyrimidine derivatives as irak4 modulators |
US10059723B2 (en) | 2011-02-28 | 2018-08-28 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
US9540395B2 (en) | 2011-02-28 | 2017-01-10 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
US8957066B2 (en) | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
GB201106817D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
EP2766355B1 (en) | 2011-10-11 | 2020-12-23 | Dana-Farber Cancer Institute, Inc. | Pyrazol-3-ones that activate pro-apoptotic bax |
PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
GB201211021D0 (en) * | 2012-06-21 | 2012-08-01 | Cancer Rec Tech Ltd | Pharmaceutically active compounds |
TW201406758A (zh) * | 2012-06-28 | 2014-02-16 | Daiichi Sankyo Co Ltd | 三環性化合物 |
GB201218862D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
GB201218850D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
US9980973B2 (en) | 2012-10-19 | 2018-05-29 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
GB201218864D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
CN104640850A (zh) * | 2012-10-26 | 2015-05-20 | 霍夫曼-拉罗奇有限公司 | 3,4-二取代的1h-吡唑和4,5-二取代的噻唑的syk抑制剂 |
AU2014228344C1 (en) | 2013-03-15 | 2019-02-07 | Biomarin Pharmaceutical Inc. | HDAC inhibitors |
CN104211692B (zh) * | 2013-06-04 | 2019-05-24 | 广东东阳光药业有限公司 | 作为欧若拉激酶抑制剂的衍生物 |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
CN104447701B (zh) * | 2013-09-17 | 2019-03-22 | 广东东阳光药业有限公司 | 吡唑类衍生物及其用途 |
WO2015085289A1 (en) | 2013-12-06 | 2015-06-11 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-cd30 antibodies |
CN105829310B (zh) | 2013-12-20 | 2019-04-12 | 阿斯特克斯治疗有限公司 | 双环杂环化合物及其治疗用途 |
SI3145929T1 (sl) * | 2014-05-23 | 2021-10-29 | Hoffmann La Roche | 5-kloro-2-difluorometoksifenil pirazolopirimidinove spojine, ki so zaviralci janusove kinaze |
JOP20150177B1 (ar) | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
JOP20150179B1 (ar) | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
WO2016024232A1 (en) | 2014-08-11 | 2016-02-18 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor |
EP3179991B1 (en) | 2014-08-11 | 2021-10-06 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor |
HUE059131T2 (hu) | 2014-08-11 | 2022-10-28 | Acerta Pharma Bv | BTK-inhibitor, PD-1-inhibitor és/vagy PD-L1-inhibitor terápiás kombinációja |
CA2967542C (en) | 2014-12-03 | 2022-11-29 | Janssen Pharmaceutica Nv | Radiolabelled mglur2 pet ligands |
EP3227295B1 (en) | 2014-12-03 | 2019-02-20 | Janssen Pharmaceutica NV | 6,7-dihydropyrazolo[1,5- ]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglu2 receptors |
CN105801563B (zh) * | 2015-01-15 | 2020-01-14 | 广东东阳光药业有限公司 | 吡唑类衍生物及其用途 |
EP3286181B1 (en) | 2015-04-22 | 2021-01-27 | Rigel Pharmaceuticals, Inc. | Pyrazole compounds and method for making and using the compounds |
WO2016202758A1 (en) * | 2015-06-18 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds |
EP3370721A4 (en) | 2015-11-06 | 2019-05-22 | Samumed, LLC | TREATMENT OF OSTEOARTHRITIS |
ES2820823T3 (es) | 2015-12-18 | 2021-04-22 | Janssen Pharmaceutica Nv | Ligandos PET mGluR2/3 radiomarcados |
SI3389727T1 (sl) | 2015-12-18 | 2020-10-30 | Janssen Pharmaceutica Nv | Radioaktivno označeni ligandi PET MGLUR2/3 |
US20170210741A1 (en) * | 2016-01-27 | 2017-07-27 | Southern Research Institute | Benzimidazole Compounds, Use As Inhibitors of WNT Signaling Pathway in Cancers, and Methods for Preparation Thereof |
WO2018166993A2 (en) | 2017-03-14 | 2018-09-20 | F. Hoffmann-La Roche Ag | Pyrazolochlorophenyl compounds, compositions and methods of use thereof |
SG11201909735YA (en) | 2017-05-22 | 2019-11-28 | Hoffmann La Roche | Therapeutic compounds and compositions, and methods of use thereof |
DE102017127039A1 (de) | 2017-11-16 | 2019-05-16 | Eppendorf Ag | Zentrifuge und Ausschwingrotor |
US11874276B2 (en) | 2018-04-05 | 2024-01-16 | Dana-Farber Cancer Institute, Inc. | STING levels as a biomarker for cancer immunotherapy |
JP7482122B2 (ja) | 2018-07-03 | 2024-05-13 | アイエフエム デュー インコーポレイテッド | Sting活性に関連する状態を治療するための化合物および組成物 |
TW202043205A (zh) | 2018-12-31 | 2020-12-01 | 美商拜歐米富士恩有限公司 | Menin-mll相互作用之抑制劑 |
EP3906026A4 (en) | 2018-12-31 | 2022-10-19 | Biomea Fusion, LLC | IRREVERSIBLE MENIN-MLL INTERACTION INHIBITORS |
US20230000842A1 (en) * | 2019-01-17 | 2023-01-05 | Samumed, Llc | Methods of treating cartilage disorders through inhibition of clk and dyrk |
CN112047932B (zh) * | 2019-06-05 | 2022-11-08 | 中国药科大学 | 吡唑类脾酪氨酸激酶抑制剂及其制备方法与用途 |
WO2021041532A1 (en) | 2019-08-26 | 2021-03-04 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
AR119857A1 (es) | 2019-08-30 | 2022-01-19 | Rigel Pharmaceuticals Inc | Compuestos de pirazol, formulaciones de los mismos y su uso para la inhibición de una proteína irak |
CN111004221B (zh) * | 2019-12-13 | 2021-02-02 | 长治学院 | 一种嘧啶/苯并咪唑杂合物、制备方法及医药用途 |
CN112592839B (zh) * | 2021-01-08 | 2022-08-19 | 浙江工业大学 | 一株降解氨基甲酸乙酯的米根霉及其应用 |
CN113149978A (zh) * | 2021-02-04 | 2021-07-23 | 中国药科大学 | 一种中间体化合物、制备方法及其用途 |
CN113549038B (zh) * | 2021-07-07 | 2023-05-23 | 常州大学 | 多取代异苯并呋喃化合物及其用途 |
CN116178358B (zh) * | 2022-11-04 | 2024-04-19 | 济南大学 | 一种靶向c-Src激酶SH3结构域的化合物及其应用 |
WO2024100115A1 (en) * | 2022-11-09 | 2024-05-16 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4431807A (en) | 1980-06-12 | 1984-02-14 | The United States Of America As Represented By The Secretary Of The Army | 4-Methyl-5-(unsubstituted and substituted phenoxy)-6-methoxy-8-(aminoalkylamino)quinolines |
US4619686A (en) | 1984-07-17 | 1986-10-28 | Eli Lilly And Company | Pyridazinylurea compounds and methods of use as herbicides |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
EP0308020A3 (en) | 1987-09-18 | 1990-12-05 | Merck & Co. Inc. | 5-(aryl and heteroaryl)-6-(aryl and heteroaryl)-1,2-dihydro-2-oxo 3-pyridinecarboxylic acids and derivatives thereof |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US5451596A (en) | 1992-12-29 | 1995-09-19 | Rhone Poulenc Rorer Pharmaceuticals Inc. | Cycloalkyl amine bis-aryl squalene synthase inhibitors |
FR2707295A1 (fr) | 1993-06-07 | 1995-01-13 | Rhone Poulenc Agrochimie | Fongicides pyrazoles substitués en position 3 par un hétérocycle. |
ES2172585T3 (es) | 1994-05-31 | 2002-10-01 | Mitsui Chemicals Inc | Derivado de benzoimidazol. |
JP3056788B2 (ja) | 1994-06-24 | 2000-06-26 | ユーロ−セルティーク,エス.エイ. | ホスホジエステラーゼivの阻害化合物および阻害方法 |
AU707323B2 (en) | 1995-03-10 | 1999-07-08 | Berlex Laboratories, Inc. | Benzamidine derivatives and their use as anti-coagulants |
CA2262403C (en) | 1995-07-31 | 2011-09-20 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
WO1997012613A1 (en) | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
JP2000507956A (ja) | 1996-04-03 | 2000-06-27 | メルク エンド カンパニー インコーポレーテッド | ファルネシル−タンパク質トランスフェラーゼ阻害剤 |
US5874452A (en) | 1996-04-03 | 1999-02-23 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
DK0906279T3 (da) | 1996-05-30 | 2003-02-03 | Hoffmann La Roche | Pyrrolderivater |
DE69835241T2 (de) | 1997-10-27 | 2007-05-31 | Agouron Pharmaceuticals, Inc., La Jolla | 4-Aminothiazol Derivate, deren Herstellung und deren Verwendung als Inhibitoren Cyclin-abhängiger Kinasen |
WO1999046244A1 (en) | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
EP1080078B1 (en) | 1998-05-22 | 2006-02-01 | Scios Inc. | Heterocyclic compounds and methods to treat cardiac failure and other disorders |
EP1058549A4 (en) | 1998-12-23 | 2003-11-12 | Bristol Myers Squibb Pharma Co | FACTOR Xa OR THROMBIN INHIBITORS |
UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
ES2197092T3 (es) | 1999-04-02 | 2004-01-01 | Bristol-Myers Squibb Pharma Company | Sulfonil arilos como inhibidores del factor xa. |
PL215901B1 (pl) | 1999-04-15 | 2014-02-28 | Bristol Myers Squibb Co | Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek |
DE60035682T2 (de) | 1999-04-28 | 2008-04-30 | Sanofi-Aventis Deutschland Gmbh | Di-aryl-säurederivate als ppar rezeptor liganden |
DE19920936A1 (de) | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
WO2001000610A1 (de) | 1999-06-23 | 2001-01-04 | Aventis Pharma Deutschland Gmbh | Substituierte benzimidazole |
FR2795726A1 (fr) | 1999-06-30 | 2001-01-05 | Aventis Cropscience Sa | Nouveaux pyrazoles fongicides |
JP4627356B2 (ja) | 1999-06-30 | 2011-02-09 | 松森 昭 | ウイルス性心筋炎の予防または治療薬剤 |
PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
BR0014076A (pt) | 1999-09-17 | 2002-10-15 | Millennium Pharm Inc | Benzamidas e inibidores correlatos do fator xa |
US6632815B2 (en) | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
CN1390206A (zh) | 1999-09-17 | 2003-01-08 | 千嬉药品公司 | 因子Xa的抑制剂 |
WO2002034721A1 (en) | 2000-10-20 | 2002-05-02 | Bristol-Myers Squibb Pharma Company | Acylsemicarbazides and their use as cyclin dependent kinase (cdk) inhibitors |
YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
HN2001000008A (es) | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
SK14082001A3 (sk) | 2000-02-05 | 2002-03-05 | Vertex Pharmaceuticals Incorporated | Deriváty pyrazolu ako inhibítory ERK a farmaceutická kompozícia, ktorá ich obsahuje |
EP1259485B1 (en) | 2000-02-29 | 2005-11-30 | Millennium Pharmaceuticals, Inc. | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa |
US20040087798A1 (en) | 2000-03-14 | 2004-05-06 | Akira Yamada | Novel amide compounds |
CA2401748A1 (en) | 2000-03-29 | 2001-10-04 | Cyclacel Limited | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders |
AU2001249865A1 (en) | 2000-04-18 | 2001-10-30 | Agouron Pharmaceuticals, Inc. | Pyrazoles for inhibiting protein kinase |
ES2236217T3 (es) | 2000-04-25 | 2005-07-16 | Bristol-Myers Squibb Company | Uso de 5.tio.,sulfinil- y sulfonilpirazolo 3,4-b)-piridinas como inhibidores de la quinasa dependiente de la ciclina. |
US6414013B1 (en) | 2000-06-19 | 2002-07-02 | Pharmacia & Upjohn S.P.A. | Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention |
IL152916A0 (en) | 2000-06-23 | 2003-06-24 | Bristol Myers Squibb Co | Heteroaryl-phenyl heterobicyclic factor xa inhibitors |
AU2001268711A1 (en) | 2000-06-23 | 2002-01-08 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
WO2002000651A2 (en) | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Factor xa inhibitors |
KR100947185B1 (ko) * | 2000-12-21 | 2010-03-15 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 조성물 |
DE10108480A1 (de) | 2001-02-22 | 2002-09-05 | Bayer Ag | Pyrazolylpyrimidine |
DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
EP1377549A1 (en) | 2001-03-12 | 2004-01-07 | Millennium Pharmaceuticals, Inc. | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor |
CA2447475A1 (en) | 2001-05-25 | 2002-12-05 | Chu-Biao Xue | Hydantion derivatives as inhibitors of matrix metalloproteinases |
DK1401837T3 (da) | 2001-06-29 | 2005-11-07 | Cv Therapeutics Inc | Purinderivater som A2B-adenosinreceptorantagonister |
EP1401831A1 (en) * | 2001-07-03 | 2004-03-31 | Chiron Corporation | Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors |
WO2003006465A1 (en) | 2001-07-13 | 2003-01-23 | Cv Therapeutics, Inc. | Partial and full agonist of a adenosine receptors |
US6897208B2 (en) | 2001-10-26 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Benzimidazoles |
FR2831536A1 (fr) | 2001-10-26 | 2003-05-02 | Aventis Pharma Sa | Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr |
IL161576A0 (en) * | 2001-10-26 | 2004-09-27 | Aventis Pharma Inc | Benzimidazoles and analogues and their use as protein kinases inhibitors |
EP1314733A1 (en) | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides as factor Xa inhibitors |
WO2003045929A1 (fr) | 2001-11-26 | 2003-06-05 | Takeda Chemical Industries, Ltd. | Derive bicyclique, procede de production de ce derive et utilisation correspondante |
WO2003053941A2 (en) | 2001-12-20 | 2003-07-03 | Bristol-Myers Squibb Company | Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases |
EP2322521B1 (en) | 2002-02-06 | 2013-09-04 | Vertex Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of GSK-3 |
AU2003286757B2 (en) | 2002-11-01 | 2009-06-04 | Merck Sharp & Dohme Corp. | Carbonylamino-benzimidazole derivatives as androgen receptor modulators |
EP1569927B1 (en) | 2002-12-04 | 2008-07-16 | Sanofi-Aventis Deutschland GmbH | IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS |
AU2003287878A1 (en) | 2002-12-11 | 2004-06-30 | 7Tm Pharma A/S | Quinoline compounds for use in mch receptor related disorders |
WO2004054515A2 (en) | 2002-12-13 | 2004-07-01 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
CA2511321A1 (en) | 2002-12-23 | 2004-07-08 | Aventis Pharma Deutschland Gmbh | Pyrazole-derivatives as factor xa inhibitors |
FR2854159B1 (fr) * | 2003-04-25 | 2008-01-11 | Aventis Pharma Sa | Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr |
US20040242559A1 (en) | 2003-04-25 | 2004-12-02 | Aventis Pharma S.A. | Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors |
GB0315657D0 (en) | 2003-07-03 | 2003-08-13 | Astex Technology Ltd | Pharmaceutical compounds |
TWI372050B (en) * | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
US20050032869A1 (en) | 2003-07-08 | 2005-02-10 | Pharmacia Italia S.P.A. | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
US20050164300A1 (en) | 2003-09-15 | 2005-07-28 | Plexxikon, Inc. | Molecular scaffolds for kinase ligand development |
EP1692113B1 (en) | 2003-11-14 | 2017-09-27 | Lorus Therapeutics Inc. | Aryl imidazoles and their use as anti-cancer agents |
EP1724263B1 (en) | 2004-03-10 | 2014-03-05 | Kureha Corporation | Basic amine compound and use thereof |
NZ555982A (en) | 2004-12-30 | 2011-01-28 | Astex Therapeutics Ltd | Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases |
JP2008526721A (ja) | 2004-12-30 | 2008-07-24 | アステックス、セラピューティックス、リミテッド | Cdk、gsk及びオーロラキナーゼの活性を調節するチアゾールおよびイソチアゾール誘導体 |
EP1968579A1 (en) | 2005-12-30 | 2008-09-17 | Astex Therapeutics Limited | Pharmaceutical compounds |
JP5523829B2 (ja) * | 2006-06-29 | 2014-06-18 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
US20110159111A1 (en) * | 2006-06-29 | 2011-06-30 | Astex Therapeutics Limited | Pharmaceutical combinations |
EP2073807A1 (en) * | 2006-10-12 | 2009-07-01 | Astex Therapeutics Limited | Pharmaceutical combinations |
-
2004
- 2004-07-02 TW TW093120042A patent/TWI372050B/zh not_active IP Right Cessation
- 2004-07-05 ES ES04743172.1T patent/ES2443995T3/es active Active
- 2004-07-05 ES ES10195498.0T patent/ES2457466T3/es active Active
- 2004-07-05 WO PCT/GB2004/002824 patent/WO2005002552A2/en active Application Filing
- 2004-07-05 DK DK04743172.1T patent/DK1648426T3/da active
- 2004-07-05 CA CA2531050A patent/CA2531050C/en not_active Expired - Fee Related
- 2004-07-05 PL PL10195498T patent/PL2305250T3/pl unknown
- 2004-07-05 EP EP04743172.1A patent/EP1648426B1/en active Active
- 2004-07-05 DK DK10195498.0T patent/DK2305250T3/da active
- 2004-07-05 JP JP2006518329A patent/JP4833059B2/ja not_active Expired - Fee Related
- 2004-07-05 AU AU2004253338A patent/AU2004253338B2/en not_active Ceased
- 2004-07-05 PT PT101954980T patent/PT2305250E/pt unknown
- 2004-07-05 US US10/564,166 patent/US7977477B2/en not_active Expired - Fee Related
- 2004-07-05 PT PT47431721T patent/PT1648426E/pt unknown
- 2004-07-05 SI SI200432125T patent/SI1648426T1/sl unknown
- 2004-07-05 CN CN2004800249288A patent/CN1845734B/zh not_active Expired - Fee Related
- 2004-07-05 SI SI200432146T patent/SI2305250T1/sl unknown
- 2004-07-05 PL PL04743172T patent/PL1648426T3/pl unknown
- 2004-07-05 MX MXPA05014223A patent/MXPA05014223A/es active IP Right Grant
- 2004-07-05 EP EP10195498.0A patent/EP2305250B1/en active Active
- 2004-07-05 NZ NZ543959A patent/NZ543959A/en not_active IP Right Cessation
-
2011
- 2011-05-26 US US13/116,121 patent/US20110224203A1/en not_active Abandoned
-
2013
- 2013-05-24 US US13/902,325 patent/US20140010892A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DK2305250T3 (da) | 2014-04-22 |
NZ543959A (en) | 2009-08-28 |
CN1845734A (zh) | 2006-10-11 |
AU2004253338A1 (en) | 2005-01-13 |
EP2305250B1 (en) | 2014-03-26 |
EP1648426B1 (en) | 2014-01-08 |
DK1648426T3 (da) | 2014-02-10 |
US20110224203A1 (en) | 2011-09-15 |
PT1648426E (pt) | 2014-03-07 |
PL1648426T3 (pl) | 2014-05-30 |
ES2457466T3 (es) | 2014-04-25 |
EP1648426A2 (en) | 2006-04-26 |
PL2305250T3 (pl) | 2014-07-31 |
PT2305250E (pt) | 2014-05-19 |
US7977477B2 (en) | 2011-07-12 |
CN1845734B (zh) | 2011-06-22 |
JP2007516194A (ja) | 2007-06-21 |
WO2005002552A2 (en) | 2005-01-13 |
WO2005002552A3 (en) | 2005-06-16 |
CA2531050C (en) | 2013-04-09 |
US20070135477A1 (en) | 2007-06-14 |
MXPA05014223A (es) | 2006-07-03 |
AU2004253338B2 (en) | 2010-02-18 |
TW200524598A (en) | 2005-08-01 |
US20140010892A1 (en) | 2014-01-09 |
SI1648426T1 (sl) | 2014-04-30 |
TWI372050B (en) | 2012-09-11 |
ES2443995T3 (es) | 2014-02-21 |
EP2305250A1 (en) | 2011-04-06 |
CA2531050A1 (en) | 2005-01-13 |
JP4833059B2 (ja) | 2011-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI2305250T1 (sl) | Benzimidazolni derivati in njih uporabo kot inhibitorji protein-kinaz | |
IL176233A0 (en) | Organophosphorous indazole derivatives and use thereof as protein kinase inhibitors | |
IL161576A0 (en) | Benzimidazoles and analogues and their use as protein kinases inhibitors | |
ZA200500680B (en) | Quinoline derivatives and their use as mycrobacterial inhibitors | |
IL173380A0 (en) | Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors | |
ZA200704888B (en) | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases | |
PL376789A1 (pl) | Pochodne aminoindazoli i ich zastosowanie jako inhibitorów kinazy | |
IL173490A0 (en) | 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors | |
SI1562589T1 (sl) | Diaminotriazoli, koristni kot inhibitorji proteinkinaz | |
PL375447A1 (en) | Protein kinase inhibitors and uses thereof | |
PL403456A1 (pl) | Pochodne 5-fenylotiazolu oraz ich zastosowanie jako inhibitorów kinazy Pi3 | |
IL161516A0 (en) | Benzimidazoles useful as protein kinase inhibitors | |
IL151045A0 (en) | 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors | |
HK1099764A1 (en) | Quinoxalines useful as inhibitors of protein kinases | |
PT1997811E (pt) | Derivados de indazol, benzoxazol e pirazolo piridina como inibidores de cinase p38 | |
HK1112895A1 (en) | 5-heteroaryl thiazoles and their use as pi3k inhibitors | |
HK1067945A1 (en) | Substituted benzazoles and use thereof as raf kinase inhibitors | |
AU2003256297A1 (en) | Benzimidazoles and benzothiazoles as inhibitors of map kinase | |
AU2003254053A8 (en) | Pyrazolopyrimidines as protein kinase inhibitors | |
PT1709018E (pt) | Derivados de acilaminotiazole e sua aplicação como inibidores | |
IL172257A0 (en) | Substituted pyrrole derivatives and their use as hmg-co inhibitors | |
ZA200606070B (en) | Substituted quinolines and their use as mycrobacterial inhibitors | |
EP1922086A4 (en) | TARGETED PROTEIN KINASE C HEMMER AND ITS USES | |
EP1877424A4 (en) | INHIBITORS OF PROTEIN KINASES AND USES THEREOF | |
AU2003215756A8 (en) | Benzimidazoles and their use as mitogen-activated- and rho-kinase inhibitors |